Skip to main content

Table 1 Overall quality of reporting rating using items from the CONSORT Statement (n= 98)

From: Quality of reporting on randomized controlled trials on recurrent spontaneous abortion in China

Item Criteria Description No. of positive trials % Cohen’sкcoefficient 95% CI
1 “Randomized” in the title or abstract Study identified as a randomized controlled in the title or abstract 10 10 1.00 -
2 Background Adequate description of the scientific background and explanation of rationale 85 87 0.67 0.43 to 0.91
3 Trial design Description of trial design (such as parallel, factorial) including allocation ratio 84 86 0.78 0.54 to 0.96
4 Participants Description of the eligibility criteria for participants 72 74 0.72 0.49 to 0.93
5 Interventions Details of the interventions intended for each group 80 82 0.62 0.41 to 0.95
6 Outcomes Definition of primary (and secondary when appropriate) outcome measures 82 84 0.75 0.48 to 0.97
7 Sample size Description of sample size calculation 0 0 0.81 0.52 to 0.99
8 Randomization Description of the method used to generate the random sequence 14 14 0.83 0.63 to 0.97
12 Statistical methods Description of the statistical methods used to compare groups for primary outcomes, subgroup analyses or adjusted analyses 71 72 1.00 -
13 Flow chart Details on the flow of participants through each stage of the trials (no. of patients randomly assigned, receiving intended treatment, completing the protocol and analyzed) 87 88 0.77 0.61 to 0.97
14 Recruitment Dates defining the periods of recruitment and follow-up 79 81 0.73 0.42 to 0.98
15 Baseline data An outline of baseline demographic and clinical characteristics of each group 3 3 0.68 0.35 to 0.92
17 Outcomes and estimation For each primary and secondary outcome, a summary of results for each group is given, along with the estimated effect size and its precision (e.g., 95% CI) 9 9 0.72 0.43 to 0.96
18 Ancillary analyses Clear statement of whether subgroup/adjusted analyses were pre-specified or exploratory 8 8 0.74 0.37 to 0.95
19 Harms Description of all important adverse events in each group 12 12 0.82 0.69 to 0.99